via NewMediaWire -- Utah Medical Products, Inc. (Nasdaq: UTMD)
reports financial results for the fourth calendar quarter (4Q)
which confirms a trend of recovery from the “COVID-19 depression”
in 2Q 2020 caused by government policies restricting medical
procedures deemed “nonessential” such as tubal ligation and loop
excision of the transformation zone. In this report, UTMD
presents 2020 successive quarterly comparisons. In summary,
4Q 2020 was UTMD’s best revenue quarter of the year, almost 2%
higher than the pre-pandemic 4Q 2019. Consolidated total
worldwide revenues for the 2020 year were 10% lower than in 2019,
after being down 26% in 2Q 2020. Direct to end user sales,
which drive UTMD’s overall profitability, were 14% lower for the
2020 year after being down 39% in the dismal 2Q 2020.
Currencies in this release are denoted as $ or USD = U.S.
Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$
or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts
throughout this report are in thousands, except per share amounts
and where noted.
Summary of Financial ResultsUTMD management believes that the
presentation of sequential 2020 quarterly comparisons provides
meaningful supplemental information to both management and
investors. Keeping in mind that results for any given three
month period in comparison with a previous year’s same three month
period may vary as a result of several factors: foreign
currency exchange rates for sales invoiced in foreign currencies,
uneven international distributor and OEM customer order patterns as
a result of purchasing larger quantities of devices at a time, and
the timing of ups and downs in government restrictions during the
pandemic. The following table shows the percent changes in
2020 quarterly revenues by sales channel compared to the same
periods of time in 2019:
Revenues [USD
denominated] |
1Q |
2Q |
3Q |
4Q |
Year |
U.S. domestic (excluding OEM) |
+ 14.5% |
(29.1%) |
(8.0%) |
(2.7%) |
( 7.5%) |
Canada domestic |
(21.7%) |
(62.9%) |
( 5.6%) |
(23.0%) |
(29.7%) |
Ireland domestic |
(26.2%) |
(48.6%) |
(18.1%) |
(31.3%) |
(31.0%) |
UK domestic |
(11.2%) |
(72.8%) |
(34.4%) |
(29.5%) |
(36.2%) |
France domestic |
(11.8%) |
(72.1%) |
(12.3%) |
(22.5%) |
(29.8%) |
Australia domestic |
( 8.6%) |
(43.0%) |
(13.6%) |
( 1.2%) |
(16.7%) |
Subtotal, Direct to End-User: |
+4.2% |
(39.1%) |
(11.1%) |
( 8.8%) |
(14.3%) |
All Other OUS (Sales to Int’l Distributors) |
( 5.2%) |
( 4.5%) |
(34.7%) |
+ 39.9% |
(3.4%) |
U.S. OEM Sales |
+ 0.7% |
+ 9.5% |
( 8.9%) |
( 1.3%) |
( 0.8%) |
Worldwide Revenues |
+ 1.6% |
(25.8%) |
(16.1%) |
+ 1.5% |
(10.1%) |
U.S. domestic sales direct to end-user facilities did not
decline as much as OUS direct to end-user facilities in 2Q 2020,
down 29% in the U.S. compared to down 63% OUS, and recovered
faster. For the year, U.S. domestic sales to end-user
facilities were 8% lower compared to 30% lower OUS. After a
good 3Q 2020 recovery, a resurgence of virus infections in 4Q 2020
slowed the recovery OUS but not in the U.S. The different OUS
4Q 2020 significant improvement in Australia was due in part to
UTMD beginning to sell directly to medical facilities in New
Zealand from its Australia facility, rather than by a third party
distributor.
UTMD subsidiary direct domestic sales in Canada, Ireland, the
United Kingdom, France, Australia and, beginning in 4Q 2020, New
Zealand, were invoiced in foreign currencies. Foreign currency
exchange (FX) rates for income statement purposes are
transaction-weighted averages. The average rates from the
applicable foreign currency to USD during 4Q 2020 and year 2020
compared to the same periods in 2019 follow:
|
4Q 20 |
4Q 19 |
Change |
2020 |
2019 |
Change |
GBP |
1.320 |
1.288 |
+ 2.5% |
1.291 |
1.277 |
+ 1.1% |
EUR |
1.192 |
1.108 |
+ 7.7% |
1.146 |
1.119 |
+ 2.4% |
AUD |
0.729 |
0.684 |
+ 6.6% |
0.692 |
0.696 |
( 0.6%) |
CAD |
0.767 |
0.757 |
+ 1.3% |
0.751 |
0.754 |
( 0.3%) |
The volatility of FX rates for OUS sales when consolidated in
USD terms continues to affect period-to-period relative financial
results because of UTMD’s significant percentage of foreign
currency sales. The FX rate impact in 4Q 2020 increased sales
by 1.1% compared to using the same FX rate as in 4Q 2019 (“constant
currency”). The 4Q 2020 FX rate impact represented about 70%
of UTMD’s increase in revenues compared to 4Q 2019. Foreign
currency revenues in 4Q 2020 were increased by $135 as a result of
a weaker USD compared to particularly the EUR and AUD. For the 2020
year as a whole, the FX rate impact was less significant,
increasing sales by $99. Foreign currency sales as a percentage of
total sales were 23.0% of total sales in 4Q 2020, and 22.3% of
total sales for the year 2020. UTMD’s 4Q 2019 and year 2019
revenues invoiced in foreign currencies represented 27.2% of total
consolidated USD sales in both periods of time.
A comparison of 4Q and Year 2020 results with the results in the
same periods of 2019, according to U.S. Generally Accepted
Accounting Principles (US GAAP), is affected by some income tax
provision adjustments not related to normal operations: 1) 4Q
2019 net income was increased $582 ($.165 increase in EPS) as a
result of final adjustments made to state of Utah tax estimates
following the December 2017 U.S. “Tax Cuts and Jobs Act” (TCJA),
enacted in late 2017, and 2) 2Q 2020 net income was decreased $225
($.061 decrease in EPS) by a long term deferred tax liability
increase on the balance of Femcare intangible assets (the
amortization of which is not tax-deductible in the UK) as a result
of a change in the UK income tax rate. The $225 increase in
deferred UK taxes over the next six years, according to US GAAP,
must be booked in the quarter in which the tax law change was
enacted. The UK decided to not reduce its corporate income
tax rate from 19% to 17% beginning in 2Q 2020, as was previously
enacted. UTMD management believes that the presentation of
results excluding the unfavorable deferred tax liability adjustment
to its 2Q 2020 net income and the favorable tax-related adjustments
to 4Q 2019 net income provides meaningful supplemental information
to both management and investors that is more clearly indicative of
UTMD’s operating results in 2020 compared to 2019. The non-US
GAAP exclusion only affects Net Income and Earnings Per
Share. All other income statement categories at and above the
EBT line were unaffected by the tax provision adjustments.
Summary of Financial ResultsThe following table provides the
sequential quarterly percentage changes in results for each income
statement category, comparing the same periods in 2020 and
2019:
Consolidated Income Statement |
1Q |
2Q |
3Q |
4Q |
Year |
Worldwide Revenues |
+ 1.6% |
(25.8%) |
(16.1%) |
+ 1.5% |
(10.1%) |
Gross Profit |
+ 0.9% |
(34.0%) |
(12.0%) |
( 7.0%) |
(13.3%) |
Operating Income |
( 5.8%) |
(55.9%) |
(17.9%) |
( 8.5%) |
(22.3%) |
Earnings Before Income Tax |
( 3.6%) |
(56.7%) |
(19.3%) |
( 9.5%) |
(22.6%) |
Net Income (US GAAP) |
- |
(62.8%) |
(20.8%) |
(21.7%) |
(26.7%) |
Earnings Per Share (US GAAP) |
+ 0.4% |
(62.0%) |
(19.0%) |
(19.8%) |
(25.4%) |
Excluding the 2Q 2020 deferred tax liability increase and
resulting “one-time” tax provision increase and the favorable tax
provision adjustments in 4Q 2019 related to the TCJA, UTMD’s non-US
GAAP Net Income and Earnings Per Share (EPS) quarterly percentage
changes follow:
Net Income (Non-US GAAP) |
- |
(56.4%) |
(20.8%) |
( 9.7%) |
(22.1%) |
EPS (Non-US GAAP) |
+ 0.4% |
(55.5%) |
(19.0%) |
( 7.5%) |
(20.7%) |
In other words, ignoring the income tax provision adjustments in
4Q 2019 and 2Q 2020, all income statement categories improved
sequentially during 2020 following the 2Q pandemic drop, compared
to the same time periods in 2019. In the following income
statement summary description, please refer to the right two
columns in the table just above for a comparison of 4Q 2020 and
year 2020 income statement results with the same periods in
2019. More detail is provided later in this report.
UTMD profit margins in 4Q 2020 and year 2020 compared to 4Q 2019
and year 2019 follow:
|
4Q 2020 (Oct – Dec) |
4Q 2019(Oct – Dec) |
2020(Jan – Dec) |
2019(Jan – Dec) |
|
Gross Profit
Margin (gross profits/sales): |
60.5% |
66.0% |
60.6% |
62.8% |
Operating Income
Margin (operating profits/sales): |
35.6% |
39.5% |
32.5% |
37.6% |
Net Income Margin (profit after taxes/sales) US GAAP: |
28.4% |
36.8% |
25.6% |
31.4% |
Net Income Margin
(non-US GAAP): |
28.4% |
31.9% |
26.1% |
30.2% |
Gross Profit in 4Q 2020 declined despite a sales increase
primarily as a result of comparison with an unusually high Gross
Profit Margin (GPM) in 4Q 2019. The decline would have been
just 2% if 4Q 2019 GPM had been the same as for 2019 year as a
whole. A 2% decline was caused by lower direct labor
productivity in both Ireland and the U.S. UTMD self-insures
its health care plan in the U.S., which experienced an unusually
high employee health care expense quarter. Year 2020 Gross
Profit was 13% lower than in 2019 as a result of 10% lower sales
together with a GPM two percentage points lower. The diluted
GPM again was due to unfavorable health care costs in the U.S.,
lower direct labor productivity in Ireland manufacturing operations
and marginally less absorption of UTMD’s fixed critical mass of
manufacturing overhead. Because the lower sales were
transitory, the Company remains very profitable even at the lower
sales levels experienced during the recent pandemic and the Company
has a significant cash reserve relative to its operational needs,
management did not cut important overhead resources which would
sacrifice future capabilities to maintain shorter term profit
margins.
Operating Income declined more than gross profit in both 4Q 2020
and year 2020. In 4Q 2020, the lower operating income was due
to a lower GPM, as 4Q 2020 sales were higher and 4Q 2020 operating
expenses were $150 lower than in 4Q 2019. For the 2020 year,
the decline was due in part to a GPM that was two percentage points
lower, but also because UTMD’s non-cash identifiable intangible
asset (IIA) amortization expense related to Femcare and the Filshie
Clip System, included in operating expenses, was 15.3% of sales in
year 2020 compared to 13.0% in year 2019. The substantially
higher IIA expense as a percentage of sales was due not only to the
lower sales in 2020 (less absorption of a fixed expense) but also
the GBP FX rate difference and the later beginning of CSI IIA
amortization in 2019.
Earnings before tax (EBT) declined more than operating income
simply because UTMD did not receive interest on its cash balances
in 2020 like it did in 2019, although average cash balances were
about 20% higher during 2020. The decline in Net Income and
EPS per US GAAP was substantially affected by tax provision
adjustments in 4Q 2019 and 2Q 2020 due to tax law changes in the
U.S. and the UK respectively. Non-US GAAP Net Income, which
excludes tax provision adjustments due to tax law changes, declined
about the same as EBT. Finally, both US-GAAP EPS and non-US
GAAP EPS declined less than Net Income as a result of the benefit
of share repurchases in 2020.
UTMD’s FX rates for balance sheet purposes are the applicable
rates at the end of each reporting period. The FX rates from the
applicable foreign currency to USD for assets and liabilities at
the end of December 2020 and the end of December 2019
follow:
Dec 31, 2020 Dec 31, 2019
Change
GBP
1.366
1.327 +
3.0%
EUR
1.223
1.123 +
8.9%
AUD
0.771
0.703 +
9.7%
CAD
0.784
0.771 + 1.6%
UTMD’s December 31, 2020 Balance Sheet remained strong with an
absence of debt. Year-end cash increased 21% to $51,590,
after using cash to pay $4,116 in cash dividends to stockholders
and an additional $6,976 to repurchase 87,000 UTMD shares in the
open market. Ending 2020 inventories were 10% lower and
ending accounts receivable were 13% lower than at the end of 2019,
despite 2% higher sales in 4Q 2020 compared to 4Q 2019. Due
to the increase in value of the foreign currencies noted
immediately above, despite $326 depreciation of foreign fixed
assets, the USD net book value of fixed assets in the UK, Ireland,
Australia and Canada increased $449 as of December 31, 2020 from
December 31, 2019. Over the one year period of time, UTMD’s
intangible asset balance declined $6,016, about 14%, despite 3%
appreciation in the GBP. Year-ending total liabilities
increased $243 because customers deposits were $259 higher at the
end of 2020. Deposits occur because UTMD, in order to reduce
collection risk, requires many of its international distributor
customers to prepay for products that they have ordered that
haven’t shipped yet. Although net profits were not as high in
2020 as in 2019, after reducing stockholders’ equity a combined
$11,092 from payment of stockholder dividends and share
repurchases, stockholders’ equity increased $1,730 from December
31, 2019 to $102,822 at December 31, 2020, an historical high for
UTMD.
Sales Total consolidated 4Q 2020 UTMD sales were $179
(1.5%) higher than in 4Q 2019. Constant currency sales were $44
(0.4%) higher. Total consolidated 2020 UTMD sales were $4,726
(10.1%) lower than in 2019. Constant currency sales in 2020 were
$4,825 (10.3%) lower than in 2019.
In 4Q 2020 compared to 4Q 2019, U.S. domestic sales were 2%
lower and OUS sales were 7% higher. For the year 2020
compared to 2019, U.S. domestic sales were 6% lower and OUS sales
were 16% lower.
Domestic sales in 4Q 2020 were $6,960 compared to $7,127 in 4Q
2019. Domestic sales for the year 2020 were $25,866 compared
to $27,493 in 2019. The components of domestic sales include
1) “direct sales” of UTMD’s medical devices to end-user facilities
(and med/surg stocking distributors for hospitals), excluding
Filshie Clip System (“Filshie device”) sales, 2) “OEM sales” of
components and other products manufactured by UTMD for other
medical device and non-medical device companies, and 3) Filshie
device sales direct to U.S. medical facilities starting in February
2019. Domestic direct sales in 4Q 2020 excluding Filshie
devices, representing 49% of total 4Q domestic sales, were $15 (0%)
lower than in 4Q 2019. Domestic direct sales for the year
2020 excluding Filshie devices, representing 50% of total domestic
sales, were $1,092 (8%) lower than in 2019. OEM sales in 4Q 2020,
representing 26% of total domestic sales, were $24 (1%) lower than
in 4Q 2019. OEM sales for the year 2020, representing 25% of total
domestic sales, were $51 (1%) lower than in 2019. Filshie device
sales direct to U.S. domestic end-user facilities were $129 (7%)
lower in 4Q 2020 compared to 4Q 2019. Filshie device sales
direct to U.S. domestic end-user facilities were $484 (7%) lower
for the year 2020 compared to Filshie device sales in 2019.
The negative impact of the COVID-19 pandemic on Filshie device
sales began in March 2020. Because Filshie device sales are a
significant portion of UTMD’s domestic business and a UTMD device
most affected by the COVID-19 pandemic, management believes the
following table might help to understand the overall 2020 pandemic
impact and recovery trend:
Filshie device sequential quarterly direct sales in the U.S.
[USD]
Year |
1Q |
2Q |
3Q |
4Q |
Year |
2020 |
1,689 |
1,135 |
1,733 |
1,756 |
6,312 |
2019 |
925 |
1,979 |
2,008 |
1,884 |
6,796 |
Total OUS sales in 4Q 2020 were $5,050 compared to $4,704 in 4Q
2019. Total OUS sales for the year 2020 were $16,312 compared
to $19,411 in 2019.
OUS sales invoiced in GBP, EUR, AUD and CAD currencies were $135
higher in 4Q 2020, and $99 higher for the year 2020 as a result of
changes in FX rates. Foreign currency OUS sales in 4Q 2020 were
$2,759, which was 55% of all OUS sales and 23% of total
consolidated 4Q 2020 sales. In comparison, foreign currency
OUS sales in 4Q 2019 were $3,221, which was 68% of all OUS sales
and 27% of total consolidated 4Q 2019 sales.
The foreign currency OUS sales for the year 2020 were $9,412,
which was 58% of all OUS sales and 22% of total consolidated 2020
sales. In comparison, foreign currency OUS sales for the year
2019 were $12,755, which was 66% of all OUS sales and 27% of total
consolidated 2019 sales. Because Filshie device sales are
also a significant portion of UTMD’s OUS business and an implanted
device most affected by the COVID-19 pandemic, management believes
the following table might help to understand the overall 2020
pandemic impact and recovery trend:
Filshie device sequential quarterly USD-denominated sales
OUS:
Year |
1Q |
2Q |
3Q |
4Q |
Year |
Direct 2020 |
1,798 |
681 |
1,426 |
1,640 |
5,545 |
2019 |
2,136 |
2,035 |
1,810 |
2,135 |
8,116 |
Distributor 2020 |
318 |
323 |
133 |
296 |
1,070 |
2019 |
494 |
487 |
437 |
340 |
1,758 |
Total OUS
2020 |
2,117 |
1,003 |
1,559 |
1,936 |
6,615 |
2019 |
2,630 |
2,523 |
2,246 |
2,475 |
9,874 |
OUS Filshie device sales obviously took a deeper hit as a result
of the pandemic than domestically in the U.S.
UTMD segments sales into the following general product
categories: gynecology/ electrosurgery, labor & delivery,
neonatal, and miscellaneous including blood pressure monitoring
kits and accessories as well as related OEM products.
In 4Q 2020 compared to 4Q 2019, worldwide gynecology/
electrosurgery device sales were 10% lower, worldwide labor &
delivery device sales were 2% higher, worldwide neonatal device
sales were 6% lower and worldwide blood pressure monitoring and
related OEM product sales were 38% higher. Devices in the
gynecology/ electrosurgery category were mostly classified as
“nonessential” during the pandemic. In the blood pressure
monitoring category, UTMD’s largest OUS distributor requested an
early $478 shipment under a new 2021 blanket purchase order.
For the year 2020 compared to 2019, worldwide gynecology/
electrosurgery device sales were 19% lower, worldwide labor &
delivery device sales were 10% lower, worldwide neonatal device
sales were 3% lower and worldwide blood pressure monitoring and
related OEM product sales were 7% higher.
Gross Profit Gross Profit results from subtracting the
costs of manufacturing and shipping products to customers from
revenues. Gross Profit was $549 (7.0%) lower in 4Q 2020 than
in 4Q 2019, after being 34% lower in 2Q 2020 and 12% lower in 3Q
2020 compared to the same time periods in 2019. The 4Q 2020
GPM was 60.5% compared to 66.0% in 4Q 2019, an unusually high GPM
quarter for UTMD. Gross Profit for the year 2020 was $3,918 (13.3%)
lower than in 2019 when the year’s revenues were 10.1% lower.
Lower direct labor productivity and less absorption of fixed
overhead costs, particularly in the 2Q and 3Q, and 22% higher U.S.
self-insured medical costs were responsible for a greater decline
in gross profit than in sales. Despite UTMD not accepting
U.S. government subsidies provided in the CARES Act, the Company
paid its manufacturing employees, who felt virus symptoms or were
exposed to others with symptoms, to not work and stay at home
during a quarantine period. In addition, in 2Q 2020, UTMD
paid U.S. employees, who were essential in continuing to produce
needed medical devices for critical care, a special bonus for
coming to work at a time when government officials were advising
people to stay at home with promises that they would be paid for
not working. The average 2020 cost for UTMD’s self-funded U.S.
health care plan increased to $13,200 (not thousands) per employee
participating in the plan from $10,800 in 2019, and the portion
paid by employees declined from 18% in 2019 to 15% in 2020.
UTMD expects its U.S. health plan expense, as well as the direct
labor productivity of its experienced workforce in the U.S. and
Ireland in general, will return to the 2019 level in 2021.
Despite the 2020 GPM decline, an average GPM exceeding 60% for
the 2020 year, with international distributor and OEM sales
representing 39% of total consolidated sales at a substantially
lower GPM, met management’s long term profitability objective.
Operating Income Operating Income results from subtracting
Operating Expenses from Gross Profit. Operating Expenses, comprised
of general and administrative (G&A) expenses, sales and
marketing (S&M) expenses and product development (R&D)
expenses, were 24.9% of sales in 4Q 2020 compared to 26.5% of sales
in 4Q 2019. Operating Expenses were 28.1% of sales for the
year 2020 compared to 25.2% of sales in 2019.
Sales were higher in 4Q 2020 than in 4Q 2019, and operating
expenses lower, yielding improvements in 4Q expenses as a
percentage of 4Q sales. On the other hand, sales were
substantially lower for the year 2020 compared to 2019, and
operating expenses about the same, yielding less favorable expenses
as a percentage of sales, and diluting UTMD’s operating profit
margin for the year as a whole.
Although the 2020 operating expense percentage of sales
increased due to the 2020 short term pandemic reduction in sales,
management continued to tightly manage operating expenses without
sacrificing resources needed for longer term growth.
|
4Q 2020 |
4Q 2019 |
2020 |
2019 |
S&M
Expense |
$ 359 |
$ 434 |
$ 1,554 |
$ 1,738 |
R&D
Expense |
111 |
125 |
486 |
483 |
G&A
Expense |
2,515 |
2,576 |
9,800 |
9,613 |
Total Operating
Expenses: |
$ 2,985 |
$ 3,135 |
$11,840 |
$11,834 |
Lower S&M expenses were due to the lack of trade show
expenses during the pandemic, and the reduction in Femcare’s direct
UK sales personnel effective in 3Q 2020. Consolidated total
S&M expenses were 3.0% of sales in 4Q 2020 and 3.7% of sales in
4Q 2019. S&M expenses were 3.7% of sales for both the
year 2020 and the year 2019.
R&D expenses were consistent with the prior year’s same
periods of time, varying only by specific project expenses. R&D
expenses were 0.9% of sales in 4Q 2020 compared to 1.1% of sales in
4Q 2019. R&D expenses for the year 2020 were 1.2% of
sales compared to 1.0% of sales in 2019.
Consolidated G&A expenses were 20.9% of sales in 4Q 2020
compared to 21.8% of sales in 4Q 2019. Consolidated G&A
expenses were 23.2% of sales in the year 2020 compared to 20.5% of
sales in 2019. Again, lower expense and higher sales in the
4Q, but lower sales and higher expense for the preceding nine
months of the year, compared to the same time periods in 2019.
G&A expenses included non-cash expense from the amortization
of IIA resulting from 1) the March 2011 Femcare Group Ltd (UK)
acquisition and 2) the amortization of IIA from the purchase of the
CSI U.S. exclusive Filshie device distribution rights effective in
February 2019.
- The initial amount of IIA for the 2011 Femcare UK purchase was
£23,998. After 9.75 years of amortization, the IIA balance is
£8,686. For both years of 2020 and 2019, the amortization
expense rate was a constant £399 per calendar quarter. The USD
amortization expense amount in each period, however, varied
according to the USD/GBP FX rate. In 4Q 2020, the Femcare
acquisition IIA amortization expense was $526 compared to $513 in
4Q 2019 for the same GBP amortization expense in both
periods. For the year 2020, the Femcare acquisition IIA
amortization expense was $2,049 compared to $2,037 in 2019.
- The initial amount of IIA for the acquisition of remaining
exclusive U.S. Filshie device distribution rights from CSI in
February 2019 was $21,000. The straight-line amortization of
this IIA is $368.4/ month over the then remaining 4.75 years of the
prior distribution agreement. After 23 months of
amortization, the CSI IIA balance as of December 31, 2020 is
$12,526. The year 2020/2019 difference in CSI IIA
amortization expense is due to the start of the amortization in
February 2019, i.e. 12 months of $368.4 monthly expense in 2020
versus 11 months of expense in 2019.
Because the two Filshie -related IIA amortization expenses
represent a significant portion of UTMD’s G&A expenses, UTMD
provides the following table that separates the IIA amortization
expenses from all other G&A expenses:
|
4Q 2020 |
4Q 2019 |
2020 |
2019 |
IIA amortization
expense |
$ 1,631 |
$ 1,618 |
$ 6,470 |
$ 6,089 |
All other G&A
expense |
884 |
958 |
3,330 |
3,524 |
Total G&A
Expenses: |
$ 2,515 |
$ 2,576 |
$ 9,800 |
$ 9,613 |
Percent of Sales: |
4Q 2020 |
4Q 2019 |
2020 |
2019 |
IIA amortization
expense |
13.6% |
13.7% |
15.3% |
13.0% |
All other G&A
expense |
7.3% |
8.1% |
7.9% |
7.5% |
Total G&A
Expenses: |
20.9% |
21.8% |
23.2% |
20.5% |
Eventually, when the two Filshie-related IIA balances are fully
amortized, stockholders can obviously look forward to a substantial
increase in EBT. The Femcare acquisition IIA amortization expense
has 5.25 more years to run at about $525 per quarter using the same
USD/GBP FX rate as in 4Q 2020.
The CSI IIA amortization expense has 3.1 more years to run at
$1,105 per quarter. Stockholders will appreciate that,
although cash flow will not be affected, annualized reported EPS
will increase $.90 after another 2.8 years, based on 4Q 2020
diluted shares outstanding and if current U.S. and Utah income tax
rates remain the same. Similarly, after another 5.25 years
annualized EPS would be $1.33 higher based on 4Q 2020 USD/GBP FX
rate, 4Q 2020 diluted shares outstanding and unchanged income tax
rates.
In summary, Operating Income in 4Q 2020 was $4,280 (35.6% of
sales) compared to $4,679 (39.5% of sales) in 4Q 2019.
Operating Income for the year 2020 was $13,708 (32.5% of sales)
compared to $17,633 (37.6% of sales) in 2019. Lower gross
profits leveraged down further by higher IIA amortization expense
absorbed by fewer sales caused the 22% lower Operating Income for
2020. In any event, UTMD’s operating income margins achieved in
2020 were excellent compared to industry peers.
Income Before Tax (EBT) EBT results from subtracting net
non‑operating expense or adding net non-operating income from or
to, as applicable, Operating Income. Consolidated 4Q 2020 EBT
was $4,286 (35.7% of sales) compared to $4,735 (40.0% of sales) in
4Q 2019. Consolidated EBT for the year 2020 was $13,840
(32.8% of sales) compared to $17,884 (38.1% of sales) in 2019.
For UTMD, non-operating expenses include bank fees, losses from
remeasuring the value of EUR cash bank balances in the UK, and GBP
cash balances in Ireland, in USD terms, and losses from the
disposition of fixed assets. Non-operating income includes
income from rent of underutilized property; investment income;
royalties from licensing UTMD’s technology to others, gains from
remeasuring the value of EUR or GBP bank balances, as applicable;
and gains from the disposition of fixed assets. Net
non-operating income results from subtracting non-operating
expenses from gross non-operating income. UTMD’s net
non-operating income in 4Q 2020 was $6 compared to $56 in 4Q 2019.
Net non-operating income for the year 2020 was $132 compared
to $252 in 2019. The lower non-operating income in 2020 was
essentially due to lower interest rates for UTMD cash balances.
As a side note for clarity of income statement results, UTMD’s
2020 and 2019 EBT, as well as all other income statement measures
above the EBT line in the Income Statements, were unaffected by tax
provision adjustments in 2020 and 2019 which resulted from a 2020
tax law change in the UK and final adjustments for the tax law
change in the U.S. in 2017. Therefore, from management’s
perspective, the 2020 year to 2019 year comparisons of Sales, Gross
Profit, Operating Income and EBT per U.S. GAAP are clear indicators
of UTMD’s financial performance, whereas the Net Income and EPS
comparisons per U.S. GAAP are not.
UTMD’s consolidated EBT was a combination of the following
partitions: The EBT of Utah Medical Products, Inc. in the U.S. was
$9,031 for the year 2020 compared to $11,549 in 2019. The 2020 EBT
of Utah Medical Products, Ltd (Ireland) was EUR 3,728 compared to
EUR 2,577 in 2019. The 2020 EBT of Femcare Ltd. in the UK was GBP
(593) compared to GBP 1,566 in 2019. The 2020 EBT of Femcare
Australia Pty Ltd was AUD 857 compared to AUD 952 in 2019. The 2020
EBT of Utah Medical Products Canada, Inc. (dba Femcare Canada) was
CAD 798 compared to CAD 1,280 in 2019. The separate EBT of
UTMD’s subsidiaries is also a function of intercompany shipments
which are eliminated in the consolidation of revenues.
EBITDA is a non-US GAAP metric that UTMD management believes is
of interest to investors because it provides meaningful
supplemental information to both management and investors that
represents profitability performance without factoring in effects
of financing, accounting decisions regarding non-cash expenses,
capital expenditures or tax environments. Although the U.S.
Securities and Exchange Commission advises that EBITDA is a
non-GAAP metric, UTMD’s non-US GAAP EBITDA is the sum of the
following elements in the table below, each of which is a US GAAP
number:
|
4Q 2020 |
4Q 2019 |
2020 |
2019 |
EBT |
$ 4,286 |
$ 4,735 |
$13,840 |
$17,884 |
Depreciation
Expense |
160 |
174 |
655 |
700 |
Femcare IIA
Amortization Expense |
526 |
513 |
2,049 |
2,037 |
CSI IIA Amortization
Expense |
1,105 |
1,105 |
4,421 |
4,053 |
Other Non-Cash
Amortization Expense |
9 |
13 |
45 |
54 |
Stock Option
Compensation Expense |
39 |
28 |
160 |
113 |
Remeasured Foreign Currency Balances |
(4) |
32 |
(45) |
76 |
UTMD non-US GAAP EBITDA: |
$ 6,121 |
$ 6,600 |
$21,125 |
$24,917 |
Period to same period change: |
(7.3%) |
|
(15.2%) |
|
In summary, UTMD’s 4Q 2020 (non-US GAAP) EBITDA declined 7.3%
compared to a 9.5% decline in EBT, and (non-US GAAP) EBITDA for the
year 2020 declined 15.2% compared to a 22.6% decline in EBT.
Management believes that the non-US GAAP 15% EBITDA decline
is more indicative of the COVID-19 pandemic negative impact on
UTMD’s 2020 operating results than the 23% decline in EBT.
Overall, the 50.1% (non-US GAAP) EBITDA as a percentage of revenues
in 2020 met management’s long term operating objective and
represents excellent 2020 operating performance in the face of
lower sales due to pandemic restrictions on medical procedures
worldwide.
Net Income Net Income in 4Q 2020 was $3,412 (28.4% of sales)
compared to $4,359 (36.8% of sales) per US GAAP in 4Q 2019.
Net Income according to US GAAP in 4Q 2019 was helped
by a $582 reduction in UTMD’s income tax provision.
Stockholders may recall that the favorable 4Q 2019 adjustment
emanated from an updated estimate of the Utah portion of the
Repatriation tax which was a result of the TCJA enacted by Congress
in December 2017, application of Utah rules for income
apportionment and further clarification of the new Foreign-Derived
Intangible Income (FDII) regime associated with the GILTI regime as
part of the TCJA.
US GAAP Net Income for the year 2020 was $10,798 (25.6% of
sales) compared to US GAAP Net Income of $14,727 (31.4% of sales)
in 2019. Net Income in 2020 included a 2Q 2020 unfavorable
$225 tax provision adjustment for a UK income tax increase on
future non-deductible IIA amortization expenses over the following
six years. The UK tax adjustment had to be recognized in the
income statement all at once according to US GAAP.
To state it simply, there was a reduction in estimated 2019
taxes that made 2019 US GAAP Net Income and EPS results better, and
an increase in 2020 estimated taxes that made 2020 US GAAP results
worse. UTMD management believes that the presentation of Net Income
and EPS results excluding the REPAT/ GILTI/ FDII tax liability
estimate adjustments in 2019 and the UK change in the long term
deferred tax liability provides meaningful supplemental information
to both management and investors that is more clearly indicative of
UTMD’s bottom line results when comparing 4Q 2020 and year 2020 to
the same periods of time in 2019.
|
4Q 2020 |
4Q 2019 |
Change |
2020 |
2019 |
Change |
Net Income (US
GAAP) |
$3,412 |
$4,359 |
(21.7%) |
$10,798 |
$14,727 |
(26.7%) |
Consolidated Tax Rate |
20.4% |
7.9% |
|
22.0% |
17.7% |
|
Net Income
(Non-GAAP, excluding tax provision adjustments) |
$3,412 |
$3,777 |
(9.7%) |
$11,023 |
$14,145 |
(22.1%) |
Consolidated
Non-GAAP Tax Rate |
20.4% |
20.2% |
|
20.4% |
20.9% |
|
Earnings per share (EPS) Diluted EPS is Net
Income divided by a time-weighted calculation of outstanding shares
plus dilution from unexercised employee and director options.
Similar to Net Income, UTMD management believes that the non-GAAP
EPS presented below are more clearly indicative of comparative
results in 2020.
|
4Q 2020 |
4Q 2019 |
Change |
2020 |
2019 |
Change |
EPS (US
GAAP) |
$0.934 |
$1.165 |
(19.8%) |
$2.941 |
$3.939 |
(25.4%) |
EPS (Non-GAAP, excluding tax provision adjustments) |
$0.934 |
$1.010 |
(7.5%) |
$3.002 |
$3.784 |
(20.7%) |
Diluted shares were 3,652,084 in 4Q 2020 compared to 3,740,458
in 4Q 2019, and 3,671,993 for the year 2020 compared to 3,738,596
in 2019. The lower diluted shares in 2020 were the combined
result of 80,000 shares repurchased in 1Q 2020, 7,000 shares
repurchased in 3Q 2020, 8,278 employee option exercises during 2020
and an employee option award of 26,300 shares in March 2020.
Outstanding shares at the end of 2020 were 3,643,035 compared to
3,721,757 at the end of calendar year 2019. The difference was due
to employee option exercises of 8,278 during 2020 offset by 87,000
shares repurchased in the open market. The number of shares used
for calculating diluted EPS was higher than ending shares because
of a time-weighted calculation of average outstanding shares plus
dilution from unexercised employee and director options. The
total number of outstanding unexercised employee and outside
director options at December 31, 2020 was 69,036 at an average
exercise price of $67.23, including shares awarded but not yet
vested. This compares to 51,690 unexercised option shares at
the end of 2019 at an average exercise price of $58.50/ share,
including shares awarded but not yet vested.
The number of shares added as a dilution factor in 4Q 2020 was
11,091 compared to 19,649 in 4Q 2019. The number of shares added as
a dilution factor for the year 2020 was 14,018 compared to 17,728
in 2019. In March 2020, 26,300 option shares were awarded to
48 employees at an exercise price of $77.05 per share. No options
were awarded in 2019. UTMD paid $1,018 ($0.280/share) in
dividends to stockholders in 4Q 2020 compared to $1,023 ($0.275/
share) paid in 4Q 2019. Dividends paid to stockholders during 4Q
2020 were 30% of 4Q 2020 Net Income. UTMD paid $4,116
($0.280/share) in dividends to stockholders in the year 2020
compared to $4,096 ($0.275/ share) paid in 2019. Dividends paid to
stockholders during 2020 were 38% of 2020 US GAAP Net Income, and
37% of 2020 non-US GAAP Net Income.
In March 2020, UTMD repurchased 80,000 of its shares in the open
market at $80.32/ share. In September 2020, UTMD repurchased 7,000
of its shares in the open market at $78.67/ share. The total
87,000 shares repurchased in 2020 were at an average price of
$80.19/ share. In May 2019, UTMD repurchased 5,000 shares at
$79.52/ share. No other shares were repurchased in 2019. The
Company retains the strong desire and financial ability for
repurchasing its shares at a price it believes is attractive for
remaining stockholders.
UTMD’s share price at the end of 2020 closed at $84.30, down 22%
from the $107.90 closing price at the end of 2019. This
compares unfavorably to the major stock market indices in 2020, all
of which appreciated: The DJIA was up 7%, S&P500 up 16% and
NASDAQ (where UTMD is traded) up 44%. The UTMD stock price
has declined during a calendar year only 5 other times in the last
22 years. The average compounded appreciation in UTMD stock
value for the last 22 years, including the 2020 decline, was 12.3%
per year, outpacing all of the major indices. Adding
dividends, UTMD stockholder value increased at an annually
compounded rate of 13.2% over the last 22 years.
Balance Sheet.At December 31, 2020 compared to the end of 2019,
UTMD cash and investments increased $8.8 million to $51.6 million
after using $4.1 million cash for dividends to stockholders and
$7.0 million cash to repurchase 87,000 UTMD shares. At December 31,
2020, working capital was $58.5 million compared to $51.4 million
at the end of 2019. Net Intangible Assets were 34.1% of total
consolidated assets on December 31, 2020 compared to 40.2% on
December 31, 2019. Even with lower demand as a result of the
COVID-19 pandemic, UTMD was able to reduce inventories $0.7 million
at December 31, 2020 from December 31, 2019. Consolidated
Accounts Receivable (net of allowances) declined $0.6 million at
December 31, 2020 compared to December 31, 2019. UTMD was
able to reduce the aging of trade receivables at the end of 2020 to
31 days, compared to aging of 36 days at the end of 2019, despite
increased financial stress of hospitals and international
distributors during the pandemic.
Stockholders’ Equity at December 31, 2020 increased $1.7 million
from the end of 2019, despite being reduced by $11.1 million from
combining $4.1 million in cash dividends and $7.0 million in stock
repurchases.
Financial ratios as of December 31, 2020 which may be of
interest to stockholders follow:1) Current Ratio =
16.42) Days in Trade Receivables (based on 4Q 2020
sales activity) = 313) Average Inventory Turns (based
on 4Q 2020 CGS and average inventories) = 3.04) 2020
YTD ROE (before dividends) = 11%
Investors are cautioned that this press release contains
forward-looking statements and that actual events may differ from
those projected. Risk factors that could cause results to
differ materially from those projected include global economic
conditions, market acceptance of products, regulatory approvals of
products, regulatory intervention in current operations, government
intervention in healthcare in general, tax reforms, the Company’s
ability to efficiently manufacture, market and sell products,
cybersecurity and foreign currency exchange rates, among other
factors that have been and will be outlined in UTMD’s public
disclosure filings with the SEC.
Utah Medical Products, Inc., with particular interest in health
care for women and their babies, develops, manufactures and markets
a broad range of disposable and reusable specialty medical devices
recognized by clinicians in over one hundred countries around the
world as the standard for obtaining optimal long term outcomes for
their patients. For more information about Utah Medical
Products, Inc., visit UTMD’s website at www.utahmed.com.
Utah Medical Products, Inc.INCOME
STATEMENT, Fourth Quarter (3 months ended December 31)(in thousands
except earnings per share):
|
4Q 2020 |
4Q 2019 |
Percent Change |
Net Sales |
$ 12,010 |
$ 11,831 |
+ 1.5% |
Gross Profit |
7,265 |
7,814 |
(7.0%) |
Operating
Income |
4,280 |
4,679 |
(8.5%) |
Income Before Tax |
4,286 |
4,735 |
(9.5%) |
Net Income (US
GAAP) |
3,412 |
4,359 |
(21.7%) |
Net Income (non-US
GAAP) |
3,412 |
3,777 |
(9.7%) |
Dilutes EPS (US GAAP) |
$ .934 |
$1.165 |
(19.8%) |
Diluted EPS (non-US GAAP) |
$ .934 |
$1.010 |
(7.5%) |
Shares Outstanding
(diluted) |
3,652 |
3,740 |
|
INCOME STATEMENT, Year (12 months ended December 31)(in
thousands except earnings per share):
|
2020 |
2019 |
Percent Change |
Net Sales |
$ 42,178 |
$ 46,904 |
(10.1%) |
Gross Profit |
25,548 |
29,466 |
(13.3%) |
Operating
Income |
13,708 |
17,633 |
(22.3%) |
Income Before Tax |
13,840 |
17,884 |
(22.6%) |
Net Income (US
GAAP) |
10,798 |
14,727 |
(26.7%) |
Net Income (non-US GAAP) |
11,023 |
14,145 |
(22.1%) |
Diluted EPS (US
GAAP) |
$ 2.941 |
$ 3.939 |
(25.4%) |
Diluted EPS (non-US GAAP) |
$ 3.002 |
$ 3.784 |
(20.7%) |
Shares Outstanding
(diluted) |
3,672 |
3,739 |
|
BALANCE SHEET
(in
thousands) |
(audited) DEC 31, 2020 |
(unaudited) SEP 30, 2020 |
(audited)DEC 31, 2019 |
|
Assets |
|
|
|
|
Cash
& Investments |
$51,590 |
$46,294 |
$42,787 |
|
Accounts & Other Receivables, Net |
4,104 |
4,277 |
4,742 |
|
Inventories |
6,222 |
6,304 |
6,913 |
|
Other
Current Assets |
346 |
385 |
444 |
|
Total Current Assets |
62,262 |
57,260 |
54,886 |
|
Property &
Equipment, Net |
11,326 |
11,036 |
10,728 |
|
Intangible Assets,
Net |
38,157 |
38,776 |
44,173 |
|
Total Assets |
$111,745 |
$107,072 |
$109,787 |
|
Liabilities &
Stockholders’ Equity |
|
|
|
|
Accounts
Payable |
788 |
651 |
1,098 |
|
REPAT Tax
Payable |
79 |
79 |
101 |
|
Other Accrued
Liabilities |
2,924 |
2,897 |
2,249 |
|
Total
Current Liabilities |
$3,791 |
$3,627 |
$3,448 |
|
Deferred Tax
Liability – Intangible Assets |
2,151 |
2,132 |
2,239 |
|
Long Term Lease
Liability Long Term REPAT Tax Payable |
3351,995 |
3461,995 |
3762,110 |
|
Deferred Income
Taxes |
651 |
557 |
521 |
|
Stockholders’
Equity |
102,822 |
98,415 |
101,093 |
|
Total Liabilities &
Stockholders’ Equity |
$111,745 |
$107,072 |
$109,787 |
|
Contact: Crystal Rios (801) 566-1200
Utah Medical Products (NASDAQ:UTMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Utah Medical Products (NASDAQ:UTMD)
Historical Stock Chart
From Apr 2023 to Apr 2024